Generic Donepezil

Buy Generic Donepezil () without prescription in Canada

In our Canadian pharmacy, you can buy Donepezil without a prescription, with delivery across Canada within 5-14 days. Discreet and anonymous packaging.

Donepezil hydrochloride is a reversible inhibitor of acetylcholinesterase, the enzyme that breaks down the neurotransmitter acetylcholine in the brain. By blocking this enzyme, donepezil increases the concentration of acetylcholine in the cerebral cortex and hippocampus, which helps to improve cognitive function, memory, and the ability to perform daily activities in patients with Alzheimer's disease. It does not cure the disease, but it can slow the progression of symptoms and provide meaningful stabilisation for a period of time.

Usual adult dose: The recommended starting dose is 5 mg taken orally once daily, preferably in the evening just before bedtime. After the patient has been on the 5 mg dose for 4 to 6 weeks, the dose may be increased to 10 mg once daily, which is the maximum recommended dose. The tablet may be taken with or without food. Donepezil should be taken at the same time each day to maintain steady blood levels. Patients should be monitored for tolerability before increasing the dose, as the 10 mg dose is associated with a higher incidence of cholinergic side effects.

Dosage form: Oral film-coated tablets, 5 mg and 10 mg. An orally disintegrating tablet (Aricept RDT) is also available in Canada.

Onset of action: Some cognitive improvement may be noticed within the first few weeks of treatment, but the full therapeutic effect typically requires 3 to 6 months of continuous daily therapy. Clinical stabilisation or modest improvement is the goal; the disease continues to progress, but the decline may be slower.

Duration of action: The elimination half-life of donepezil is approximately 70 hours, allowing for once-daily dosing. Steady-state plasma concentrations are reached within 15 to 21 days. The clinical benefit persists only with ongoing treatment; discontinuation leads to a gradual loss of effect over several weeks.

Alcohol recommendation: Alcohol consumption should be limited or avoided during treatment with Donepezil. Alcohol can worsen cognitive function and increase the risk of side effects such as nausea, vomiting, and dizziness. It may also interfere with the therapeutic benefits of the medication.

Most common side effects: Nausea, diarrhoea, insomnia, vomiting, muscle cramps, fatigue, and decreased appetite. These effects are usually mild to moderate, are most common during the first few weeks of therapy or after dose increases, and often resolve with continued treatment. They are more frequent at the 10 mg dose than at 5 mg.

Would you like to try Donepezil without a prescription?

General Information about Donepezil

• INN (International Nonproprietary Name): Donepezil (as donepezil hydrochloride).
• Brand names available in Canada: Aricept® (Pfizer Canada Inc.) is the original brand-name product. Generic versions are widely available and include APO-Donepezil (Apotex Inc.), TEVA-Donepezil (Teva Canada Limited), Sandoz Donepezil (Sandoz Canada Inc.), PMS-Donepezil (Pharmascience Inc.), and others. Orally disintegrating tablets are marketed as Aricept RDT® and generics.
• ATC code: N06DA02 (donepezil; centrally acting anticholinesterases).
• Dosage forms and strengths: Oral film-coated tablets: 5 mg and 10 mg. Orally disintegrating tablets: 5 mg and 10 mg.
• Manufacturers in Canada: Pfizer Canada Inc. (Aricept), Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. First marketed in Canada in 1997. DINs: 02232034 (Aricept 5 mg), 02232035 (Aricept 10 mg), and numerous generic DINs.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. A valid prescription from a licensed Canadian healthcare professional is required.

Mechanism of Action and Pharmacology

Donepezil is a piperidine derivative and a specific, reversible inhibitor of the enzyme acetylcholinesterase (AChE). In the brain of patients with Alzheimer's disease, there is a significant loss of cholinergic neurons and a marked reduction in the synthesis and release of acetylcholine, a neurotransmitter essential for memory and cognitive function. By inhibiting AChE, donepezil prevents the breakdown of acetylcholine in the synaptic cleft, thereby increasing its concentration and prolonging its action. This enhanced cholinergic neurotransmission in the cerebral cortex and hippocampus is believed to underlie the modest symptomatic improvement seen in Alzheimer's disease. Donepezil has a high degree of selectivity for AChE in the brain compared with butyrylcholinesterase (BuChE) found in peripheral tissues, which may contribute to a more favourable gastrointestinal side-effect profile than older, non-selective cholinesterase inhibitors. After oral administration, donepezil is well absorbed, with peak plasma concentrations reached in 3 to 4 hours. Food does not affect absorption. The drug is approximately 96% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein. Donepezil is extensively metabolised in the liver by cytochrome P450 2D6 (CYP2D6) and 3A4 (CYP3A4), and to a lesser extent by glucuronidation. The elimination half-life is approximately 70 hours, permitting once-daily dosing. Steady-state concentrations are achieved within 15 to 21 days. The drug is excreted in urine and faeces as metabolites and unchanged drug.

Indications

• For the symptomatic treatment of mild, moderate, and severe Alzheimer's disease. Donepezil can modestly improve cognitive function, global clinical status, and activities of daily living in some patients. It does not alter the underlying neurodegenerative process, and the disease continues to progress over time.
• Not indicated for other types of dementia, such as vascular dementia or Lewy body dementia, though it is sometimes used off-label for these conditions under specialist guidance.
• Safety and efficacy in children and adolescents under 18 years of age have not been established.

Important Warnings and Precautions

At-risk groups

• Pregnancy: There are no adequate and well-controlled studies of donepezil in pregnant women. It should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Women of childbearing potential should use effective contraception during treatment.
• Breastfeeding: It is not known whether donepezil is excreted in human breast milk. Because many drugs are excreted in human milk, breastfeeding is not recommended during treatment. A decision must be made whether to discontinue breastfeeding or to discontinue the drug.
• Paediatrics (< 18 years): Safety and efficacy have not been established. Donepezil is not indicated for paediatric use.
• Elderly: No dose adjustment is required based on age alone. However, elderly patients are more likely to have decreased renal or hepatic function, and they may be more susceptible to the cholinergic side effects of donepezil, such as nausea, vomiting, and diarrhoea. The starting dose of 5 mg should be maintained for at least 4-6 weeks before considering an increase to 10 mg.
• Cardiovascular conditions: Because of its cholinergic activity, donepezil can cause bradycardia (slow heart rate), particularly in patients with sick sinus syndrome or other supraventricular conduction disorders. Syncope (fainting) has been reported. Use with caution in patients with a history of cardiac conduction abnormalities, bradycardia, or those taking medications that lower heart rate. An electrocardiogram (ECG) may be considered before starting therapy.
• Gastrointestinal conditions: Cholinesterase inhibitors can increase gastric acid secretion and may predispose patients to gastrointestinal bleeding, especially those with a history of peptic ulcer disease or those taking non-steroidal anti-inflammatory drugs (NSAIDs). Patients should be monitored for signs of active or occult gastrointestinal bleeding. Donepezil can also cause diarrhoea, nausea, and vomiting, which may lead to dehydration; adequate fluid intake is important, particularly in elderly patients.
• Genitourinary conditions: Cholinomimetics can cause bladder outflow obstruction. Use with caution in patients with benign prostatic hyperplasia (BPH) or other conditions that predispose to urinary retention.
• Respiratory conditions: Because of its cholinomimetic action, donepezil should be used with caution in patients with a history of asthma or chronic obstructive pulmonary disease (COPD). It may increase bronchial secretions and bronchoconstriction.
• Seizure disorders: Cholinesterase inhibitors may lower the seizure threshold. Use with caution in patients with a history of seizures.
• Anaesthesia: Donepezil, as a cholinesterase inhibitor, may exaggerate succinylcholine-type muscle relaxation during anaesthesia. Anaesthetists should be informed that the patient is taking donepezil before elective surgery.
• Neuroleptic Malignant Syndrome (NMS): NMS, a potentially life-threatening condition characterised by hyperthermia, muscle rigidity, altered consciousness, and autonomic instability, has been reported very rarely in patients taking donepezil, particularly when combined with antipsychotics or other dopaminergic drugs. If symptoms occur, donepezil should be discontinued, and appropriate treatment initiated.
• Allergy: Do not take Donepezil if you have a known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipient in the tablet formulation.

Driving and alcohol

Donepezil may cause dizziness, fatigue, and muscle cramps, particularly at the start of therapy and after dose increases. Patients should not drive, operate heavy machinery, or engage in hazardous activities until they have determined how the medication affects their cognitive and motor function. Alcohol should be limited or avoided because it can worsen the side effects of donepezil, such as dizziness and drowsiness, and may further impair cognitive function in patients with Alzheimer's disease.

Dosage Instructions

• Initial dose: 5 mg taken orally once daily, preferably in the evening just before bedtime. This dose should be maintained for at least 4 to 6 weeks to allow the patient to develop tolerance and to assess clinical response.
• Maintenance dose: After 4 to 6 weeks, the dose may be increased to 10 mg once daily if the 5 mg dose is well tolerated. The 10 mg dose is the maximum recommended daily dose. Some patients may remain on 5 mg if they experience bothersome side effects at the higher dose, and this may still provide clinical benefit.
• Administration: The tablet should be swallowed whole with a glass of water, and may be taken with or without food. The orally disintegrating tablet (Aricept RDT) should be placed on the tongue and allowed to dissolve; it should not be swallowed whole or chewed. If a dose is missed, it should be taken as soon as remembered on the same day; if it is close to the time of the next dose, the missed dose should be skipped and the regular schedule resumed. Do not double the dose.
• Discontinuation: Abrupt discontinuation of donepezil will lead to a gradual decline in cognitive function over several weeks, returning to the level expected without treatment. There is no withdrawal syndrome. If therapy is interrupted for more than 7 days, it should be restarted at the 5 mg dose and re-titrated after 4-6 weeks.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Nausea, diarrhoea, and headache.
• Common side effects (1-10%): Insomnia, vomiting, muscle cramps, fatigue, anorexia (loss of appetite), dizziness, and abdominal pain. Weight loss has been reported. These effects are more frequent at the 10 mg dose than at 5 mg, and they often resolve with continued treatment or dose reduction. Taking the medication with food does not reduce the incidence of gastrointestinal side effects.
• Less common but serious side effects: Bradycardia (slow heart rate), syncope (fainting), seizures, gastrointestinal haemorrhage (bleeding), urinary retention, and extrapyramidal symptoms (tremor, rigidity). Neuroleptic Malignant Syndrome has been reported very rarely. Hepatitis and pancreatitis have also been observed in post-marketing reports.
• Contraindications: Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipient in the tablet. Pregnancy and breastfeeding are not absolute contraindications, but use only if clearly necessary.

Drug Interactions

• Anticholinergic agents: Drugs with anticholinergic activity (e.g., atropine, oxybutynin, tricyclic antidepressants, first-generation antihistamines) may antagonise the effects of donepezil and should be avoided when possible. Their use could worsen cognitive function.
• Cholinergic agonists and cholinesterase inhibitors: Additive cholinergic effects may occur if donepezil is used with other cholinomimetics (e.g., bethanechol) or other cholinesterase inhibitors (e.g., rivastigmine, galantamine). This combination is not recommended due to the risk of excessive parasympathetic stimulation (nausea, vomiting, bradycardia).
• Drugs that slow heart rate: Beta-blockers (e.g., metoprolol, atenolol), calcium channel blockers (e.g., diltiazem, verapamil), digoxin, and amiodarone may add to the bradycardic effect of donepezil. Heart rate should be monitored, especially when therapy is initiated or the dose is increased.
• CYP2D6 and CYP3A4 inhibitors: Ketoconazole, itraconazole, erythromycin, clarithromycin, fluoxetine, paroxetine, and quinidine may increase donepezil plasma concentrations. While dose adjustment is not routinely required, patients should be monitored for increased cholinergic side effects.
• CYP2D6 and CYP3A4 inducers: Rifampicin, carbamazepine, phenytoin, and St. John’s wort may decrease donepezil plasma concentrations, potentially reducing its therapeutic efficacy. A dose increase may be considered, but this has not been formally studied.
• Non-steroidal anti-inflammatory drugs (NSAIDs): The risk of gastrointestinal bleeding may be increased when donepezil is combined with NSAIDs, aspirin, or corticosteroids. Patients should be monitored for signs of gastrointestinal bleeding, and gastroprotective therapy (e.g., a proton pump inhibitor) may be considered in high-risk individuals.
• Alcohol and food: Alcohol can worsen the central nervous system side effects of donepezil and should be limited. Food does not affect the absorption of donepezil, but taking the tablet with food does not reduce gastrointestinal side effects.

Practical Advice

• Administration: Take Donepezil once daily, preferably in the evening. Swallow the film-coated tablet whole with water; the orally disintegrating tablet should be allowed to dissolve on the tongue without water. Maintain a consistent daily schedule. If you miss a dose, take it as soon as you remember on the same day, but never double up. If treatment is interrupted for more than a week, consult your doctor before restarting.
• Monitoring: No routine laboratory monitoring is required for most patients. However, body weight should be checked periodically, as weight loss can occur. Heart rate should be monitored, especially in patients with cardiac conditions. Patients should be observed for signs of gastrointestinal bleeding, particularly if they are taking NSAIDs or anticoagulants. Caregivers should report any new or worsening symptoms to the prescribing physician.
• Storage: Store at room temperature (15-30 °C) in a tightly closed container, protected from moisture and light. Keep out of the reach and sight of children.
• Lifestyle: Donepezil is a symptomatic treatment for Alzheimer's disease; it does not stop the underlying neurodegeneration. A structured daily routine, a calm environment, and cognitive stimulation can help the patient function as well as possible. Maintain adequate hydration, especially if diarrhoea or vomiting occurs. Avoid alcohol, which can worsen cognitive side effects. Inform all healthcare providers, including dentists and surgeons, that the patient is taking donepezil, as it may affect anaesthesia and other medications.
• When to seek medical review: Contact the doctor if the patient experiences severe nausea, vomiting, diarrhoea leading to dehydration, fainting, a very slow or irregular heartbeat, signs of gastrointestinal bleeding (black or bloody stools, vomiting blood), difficulty urinating, or seizures. Seek emergency medical attention for severe allergic reactions (swelling of the face, tongue, or throat, difficulty breathing) or signs of Neuroleptic Malignant Syndrome (high fever, severe muscle stiffness, confusion).
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other cholinesterase inhibitors: Rivastigmine (Exelon®), which is available as an oral capsule and a transdermal patch, and galantamine (Reminyl®), which also modulates nicotinic receptors, are alternatives for mild to moderate Alzheimer's disease. The transdermal patch may be preferred for patients who have difficulty swallowing or who experience significant gastrointestinal side effects with oral therapy.
• Memantine (Ebixa®): An NMDA receptor antagonist that works through a different mechanism, regulating glutamate activity. It is used for moderate to severe Alzheimer's disease, often in combination with a cholinesterase inhibitor. Memantine does not have the cholinergic side effects of donepezil.
• Combination therapy: Fixed-dose combination products containing donepezil and memantine (e.g., Namzaric®) are available in some markets but not in Canada; however, the two drugs can be prescribed separately. Combining a cholinesterase inhibitor with memantine may provide additive symptomatic benefit.
• Non-pharmacological approaches: Cognitive stimulation therapy, behavioural management strategies, caregiver support, and a safe, structured environment are essential components of Alzheimer's disease management and should always accompany pharmacotherapy.

Clinical Efficacy

Donepezil has been studied extensively in patients with mild, moderate, and severe Alzheimer's disease. In pivotal randomised, double-blind, placebo-controlled trials, donepezil 5 mg and 10 mg once daily produced statistically significant improvements in cognitive function as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and global clinical impression scores compared with placebo. The mean difference in ADAS-cog score was approximately 2-3 points over 24 weeks, which represents a clinically meaningful delay in cognitive decline of about 6 months. Patients who continued donepezil over 1-2 years showed slower functional decline compared with historical controls, though the disease continued to progress. In severe Alzheimer's disease, donepezil improved cognitive function and global assessment compared with placebo, with a favourable safety profile. The 10 mg dose generally provides greater cognitive benefit than the 5 mg dose, but with a higher incidence of cholinergic side effects. Canadian clinical practice guidelines recommend a trial of a cholinesterase inhibitor, such as donepezil, for eligible patients with Alzheimer's disease, with the understanding that the benefits are modest and should be weighed against tolerability. The drug has no effect on the underlying pathology of the disease.

Important:

Donepezil is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It is a symptomatic treatment for Alzheimer's disease and does not cure the underlying condition. The most common side effects are nausea, diarrhoea, and vomiting, which can lead to dehydration, especially in elderly patients. This medication can cause a slow heart rate and fainting, particularly in patients with pre-existing heart conditions. If a patient stops donepezil for more than a few days, therapy should be restarted at the lowest dose and re-titrated gradually. Alcohol should be avoided, as it can worsen side effects and cognitive impairment. Do not use donepezil if you are pregnant or breastfeeding unless specifically directed by your doctor. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Donepezil - Shipping across Canada